Phase 3 Head and Neck Cancer Trial, Recruiting NCT04448522 Sponsor: Sun Yat-sen University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT04448522
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of nose and throat cancer called non-keratinizing nasopharyngeal carcinoma (a particular subtype confirmed by tissue testing)
  • People whose cancer has been classified as a certain stage (Stage II or III) based on how far it has spread, according to standard cancer staging guidelines
  • People aged between 18 and 70 years old
  • People who are reasonably physically well and able to carry out normal daily activities, as measured by a standard health scoring tool (confirm with trial site)
  • People whose bone marrow is functioning normally based on blood tests
  • People whose cancer responded well to 3 cycles of a specific chemotherapy combination (called GP induction chemotherapy), showing either a partial or complete response
  • People whose levels of a virus marker in the blood (EBV DNA) dropped to zero after completing those 3 chemotherapy cycles
  • People whose liver and kidney function results fall within acceptable ranges on blood and urine tests
  • People who have signed a written consent form agreeing to take part in the trial

Who may not be able to join:

  • People who have a different subtype of the same cancer, specifically one called keratinized squamous cell carcinoma or basal squamous cell carcinoma
  • People whose cancer has come back after previous treatment, or has spread to other parts of the body
  • People whose cancer did not respond to, or continued to grow during, 3 cycles of GP induction chemotherapy
  • People who still have detectable levels of the EBV virus marker in their blood after completing those 3 chemotherapy cycles
  • People who are currently pregnant or breastfeeding (the trial notes that pregnancy testing should be considered for women who could become pregnant, and that effective contraception is strongly emphasised during treatment)
  • People who have had another serious cancer in the past, except for certain fully treated skin cancers or a very early-stage cervical condition (confirm specific details with trial site)
  • People whose cancer in the nose/throat area has already been treated with chemotherapy or surgery (other than a biopsy taken purely for diagnosis)
  • People with certain serious other health conditions that could make participation risky or difficult, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, or significant mental illness

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-20-87343624

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
18 August 2020
Est. completion
1 August 2026

Where this trial is recruiting

🇨🇳 China 🇸🇬 Singapore

Primary endpoints

Progress-free survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov